After biochemical recurrence following radical prostatectomy, external beam radiation therapy (EBRT) reduces the risk of prostate-cancer-specific mortality. However, many men with a detectable serum PSA level will never experience clinical progression. New definitions of biochemical recurrence could help to determine the most appropriate candidates and time points for salvage EBRT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wiegel, T. et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J. Clin. Oncol. 27, 2924–2930 (2009).
Thompson, I. M. et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J. Urol. 181, 956–962 (2009).
Trock, B. J. et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299, 2760–2769 (2008).
Stephenson, A. J. et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J. Clin. Oncol. 25, 2035–2041 (2007).
Lepor, H. et al. Clinical evaluation of a novel method for the measurement of prostate-specific antigen, AccuPSA(TM), as a predictor of 5-year biochemical recurrence-free survival after radical prostatectomy: results of a pilot study. BJU Int. 109, 1770–1775 (2012).
Mir, M. C. et al. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2013.08.022.
Eggener, S. E. et al. Comparison of models to predict clinical failure after radical prostatectomy. Cancer 115, 303–310 (2009).
Kibel, A. S. Treat now or later: the dilemma of postoperative radiotherapy. Eur. Urol. 61, 452–454 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Eifler, J., Cookson, M. Could sensitive PSA assays expedite salvage radiotherapy?. Nat Rev Urol 11, 14–15 (2014). https://doi.org/10.1038/nrurol.2013.276
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2013.276
